Bridgebio sets its heart on besting Pfizer

Bridgebio has long claimed that its amyloidosis contender, acoramidis, is more potent than Pfizer’s similarly acting blockbuster Vyndaqel. These claims will soon be put to the test, with the first data from the phase 3 Attribute-CM study of acoramidis due by the end of the year.

The readout, from part A of the study, will include 12-month results on the six-minute walk test, the primary endpoint, and Kansas City cardiomyopathy questionnaire scores. On the former, Bridgebio believes that, in order to differentiate acoramidis from Vyndaqel, it will need to show a decline from baseline of 20 metres or less.